967 reports of this reaction
1.7% of all ATEZOLIZUMAB reports
#12 most reported adverse reaction
HYPOTHYROIDISM is the #12 most commonly reported adverse reaction for ATEZOLIZUMAB, manufactured by Genentech, Inc.. There are 967 FDA adverse event reports linking ATEZOLIZUMAB to HYPOTHYROIDISM. This represents approximately 1.7% of all 56,768 adverse event reports for this drug.
Patients taking ATEZOLIZUMAB who experience hypothyroidism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOTHYROIDISM is a less commonly reported adverse event for ATEZOLIZUMAB, but still significant enough to appear in the safety profile.
In addition to hypothyroidism, the following adverse reactions have been reported for ATEZOLIZUMAB:
The following drugs have also been linked to hypothyroidism in FDA adverse event reports:
HYPOTHYROIDISM has been reported as an adverse event in 967 FDA reports for ATEZOLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOTHYROIDISM accounts for approximately 1.7% of all adverse event reports for ATEZOLIZUMAB, making it a notable side effect.
If you experience hypothyroidism while taking ATEZOLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.